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Pleural empyema 
Pleural empyema 
• Pleural empyema is the presence of pus in the 
pleural space. 
• It was first described in the 5th century B.C. by 
Hippocrates in his aphorisms: “pleuritis that 
does not clear up in fourteen days results in 
empyema”. 
http://www.researchgate.net/profile/Valentina_Pinelli/publication/49736268_Practi
cal_management_of_pleural_empyema/file/504635166b0a21eb33.pdf 
Pleural empyema 
http://www.medicalexhibits.com/medical_exhi
bits_image.php?exhibit=10151_02X 
http://quizlet.com
/3167733/pulmon
ary-pathology-
flash-cards/ 
Autopsy specimen of the contents of the chest viewed from behind 
demonstrates encasement of the left lung by thick purulent exudate which is 
characteristic of  empyema.  
http://radiopaedia.org/cases/empyema-gross-
pathology 
Epidemiology of Empyema 
• PPE develop in up to 57% of patients hospitalized with 
bacterial pneumonias. 
• The presence of PPE increases mortality in these 
patients by about three- to six-fold. 
• Among adults, the incidence of empyema increased 
significantly by 1.2-fold during a nine-year period 
between 1995 and 2003 in a North American study.13 
Another study, from Utah in the United States, showed 
a more than six-fold increase in death rate from 
empyema during a 4-year period between 2000 to 
2004 when compared to death rate from empyema 
during 1950 to 1975. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PM
C2998927/ 
Risk factors for Empyema  
• Empyema may develop as a complication of 
pneumonia, or may follow surgery, trauma, 
iatrogenic procedures, or, rarely, bronchial 
obstruction from a tumour or foreign body.  
• Pleural infection may also occur as a ‘‘primary’’ 
infection, without evidence of lung parenchymal 
infection. 
• Approximately one third of cases occur in the 
absence of any identifiable risk factors, 
suggesting that variation in bacterial virulence or 
host immune defence may also play important 
role in empyema development. 
 
Pathophysiologic classification of 
pleural effusion 
• Pleural effusion secondary to pneumonia is 
termed parapneumonic effusion.  
• Most of these effusions remain sterile and are 
resolved with antibiotic therapy - uncomplicated 
parapneumonic effusion, but 
• infections of the pleural space develop in a small 
subset of patients and require drainage for full 
recovery - complicated parapneumonic effusion. 
• Without effective drainage, complicated 
parapneumonic, effusion progresses to frank 
intrapleural pus  or empyema. 
Bacteriology 
• All patients suspected of having a parapneumonic effusion should undergo 
a thoracentesis, unless the effusion is very small .  
• Bacteriological studies should include a Gram stain and aerobic and 
anaerobic cultures. 
• The majority of culture-positive effusions are due to Aerobic organisms, 
while up to 15% are caused exclusively by anaerobic bacteria, and the 
remainder are due to multiple, usually both aerobic and anaerobic, 
organisms.  
• Streptococci (often Streptococcus pneumoniae) and Staphylococci (mostly 
Staphylococcus aureus) usually dominate aerobic Gram-positive isolates,  
• whilst Escherichia coli, Klebsiella spp., Pseudomonas spp., and 
Haemophilus influenzae are the most common aerobic Gram-negative 
isolates.  
• E. coli and anaerobic organisms are often found in combination with other 
organisms.  
• The most frequent anaerobic isolates are Bacteroides spp. and 
Peptostreptococcus. 
• Occasionally, Actinomyces spp., Nocardia spp., or fungi (most frequently 
Aspergillus) may be the cause of an empyema. 
http://www.ersj.org.uk/content/10/5/1150.full
.pdf 
Pathophysiology of empyema 
• Parapneumonic effusions and empyema usually develop along the 
following stages: 
1. The pleuritis sicca stage 
• The inflammatory process of the pulmonary parenchyma extends to the 
visceral pleura, causing a local pleuritic reaction. This leads to a pleural 
rub and the characteristic pleuritic chest pain, which originates from the 
sensitive innervation of the adjacent parietal pleura. 
• A significant number of patients with pneumonia report pleuritic chest 
pain without developing a pleural effusion, suggesting that the 
involvement of the pleura may be limited to this stage in many cases of 
pneumonia. 
2.    The exudative stage 
• The ongoing inflammatory process leads to a mediator-induced 
increased permeability of local tissue and of regional capillaries.  
• The subsequent accumulation of fluid in the pleural space is probably 
the combined result of the influx of pulmonary interstitial fluid  and of a 
local microvascular exudate. The fluid is usually clear and sterile, 
cytological specimens show a predominance of neutrophils, the pH is 
normal and the lactate dehydrogenate (LDH) activity is <1,000 
international units (IU). 
http://www.ersj.org.uk/content/10/5/1150.full.pdf 
Pathophysiology of empyema 
3.    The fibropurulent stage 
• This stage may develop quickly (within hours) in patients who are not 
receiving antibiotics, or who are treated with ineffective antibiotics.  
• It is characterized by the deposition of fibrin clots and fibrin membranes 
("sails") in the pleural space, which lead to loculations with increasing 
numbers of isolated collections of fluid. 
• It is usually accompanied by (and caused by) bacterial invasion from the 
pulmonary parenchyma. The fluid is often turbid or frank pus. Cytology 
shows neutrophils and often degenerated cells, and Gram stains and 
bacterial cultures are usually positive.  
• The metabolic and cytolytical activity in these effusions is high, as reflected 
by low pH values (<7.2), and high LDH activities (often >1,000 IU). 
4.  The organizational stage 
• This final stage is characterized by the invasion of fibroblasts, leading to the 
transformation of interpleural fibrin membranes into a web of thick and 
nonelastic pleural peels.  
• Functionally, gas exchange is often severely impaired on the side of the 
organizing empyema ("trapped lung").  
• The further course may vary from spontaneous healing with persistent 
defects of lung function to chronic forms of empyema with high risks for 
further complications, such as bronchopleural fistula, lung abscess, or 
"empyema necessitatis" (spontaneous perforation through the chest wall). 
 http://www.ersj.org.uk/content/10/5/1150.full.pdf 
Empyema 
Early organization phase 
http://www.kidsdoc.at/en/pleural_effusion.html 
Clinical presentations 
• Chills, fever, dyspnea, chest pain, or referred pain; 
recent pulmonary or contiguous infection in the 
oropharynx, mediastinum, or subdiaphragmatic area;  
• Symptoms suggesting adjacent tissue infection 
extending to the pleura, i.e., dysphagia, dyspepsia, 
hiccups, or pharyngeal, abdominal, back, or shoulder 
pain; recent instrumentation, surgery, or trauma of the 
chest, oropharynx, esophagus, or abdomen; delayed or 
incomplete response to appropriate medical therapy 
for an infection that could extend to the pleura;  
• Patients with pneumonia due to infection with aerobic 
bacteria usually suffer from an acute febrile illness, 
whilst patients with anaerobic infections tend to 
present with a more subacute or chronic condition, 
with a longer duration of symptoms and frequent 
weight loss. 
 
http://cid.oxfordjournals.org/content/22/5/74
7.full.pdf 
Physical examination 
• Physical examination. Diminished breath sounds or basilar 
dullness to percussion; pleural friction rub; bronchophony or 
egophony above effusion or adjacent to pneumonia; tracheal 
or mediastinal shift; scoliosis following a respiratory infection 
(in children); focal chest wall heat, erythema, swelling, and/or 
pain (rare); draining dermal sinuses (rare); hyperpyrexia, 
shock, tachypnea (>30 respirations/min), and lor altered 
consciousness (all of which may be indicative of 
disproportionately severe infection). 
• Clinical course. Rapid onset of clinical deterioration and sepsis 
with respiratory failure; persistent fever, sepsis, and/or organ 
failure despite appropriate antibiotic therapy (in a susceptible 
patient); worsening clinical and laboratory indicators of 
infection despite appropriate antibiotic therapy. 
http://cid.oxfordjournals.org/content/22/5/74
7.full.pdf 
Diagnosis  
Pleural fluid 
• Pleural fluid. Cloudy, bloody, or purulent; WBC 
count >50,000 X 10x9IL (usually); pH level 
<7.1, lactic dehydrogenase level >1,000 lUlL; 
glucose level, <40 mg/dL; positive smear 
stains or cultures; fetid ( 2/3 of anaerobic 
empyemas). 
• Findings indicating severe infection. 
Neutropenia or neutrophilia with immature 
forms. 
http://cid.oxfordjournals.org/content/22/5/74
7.full.pdf 
Ultrasonography 
• Ultrasonography is an easy, accessible, 
economical and helpful tool to identify and 
quantify pleural septation at an early stage 
Sonographic appearance of parapneumonic effusions: 
“Complex” effusion in which multiple loculations due to 
fibrin membranes are visible 
http://www.researchgate.net/profile/Valentina_Pinelli/publication/49736268_Practi
cal_management_of_pleural_empyema/file/504635166b0a21eb33.pdf 
Sonographic appearancy of 
empyema 
Sonographic (A) and thoracoscopic appearance (B) of a complex septated 
parapneumonic effusion with fibrin membranes in the pleural cavity. 
http://www.researchgate.net/profile/Valentina_Pinelli/publication/49736268_Practi
cal_management_of_pleural_empyema/file/504635166b0a21eb33.pdf 
Findings on CT 
 • Features suggestive of an empyema include: 
• enhancing thickened pleura (split pleura sign) 
whereas pleural effusion have thin 
imperceptable pleural surfaces  
• locules of gas absent unless recent 
thoracocentesis 
• obvious septations 
• associated consolidation 
• associated adjacent infeciton (e.g. sub-
diaphragmatic abscess) 
http://radiopaedia.org/articles/empyema-vs-
pleural-effusion 
CT 
• The split pleura sign is seen with pleural 
empyemas and is considered the most reliable CT 
sign helping to distinguish an empyema from a 
peripheral pulmonary abscess.  
• The sign results from fibrin coating both the 
parietal and pleural surface of the pleura with 
resulting ingrowth of blood vessels with 
accompanying enhancement.  
• Both layers of the pleura can then be visualised as 
linear regions of enhancement that come 
together at the margins of the collection. 
http://radiopaedia.org/articles/split-pleura-
sign 
The Split Pleura Sign 
Contrast-enhanced transverse CT scan shows 
empyema between thickened parietal 
(arrowheads) and visceral (arrow) pleural 
layers: the split pleura sign. 
http://pubs.rsna.org/doi/full/10.1148/radiol.2431041658 
Empyema 
Coronal reformatted chest CT 
images show a lesion in the 
right upper lobe with internal 
air-filled cavity, thick irregular 
wall (green arrowheads) and 
another lesion in the left 
lower lung with internal fluid, 
thin wall (yellow arrowhead) 
and adjacent compression of 
the lung tissue (yellow arrows 
and box). The right upper 
lobe lesion is an abscess and 
the left lower lung lesion is an 
empyema 
http://radiologyinthai.blogspot.com/2010/01/l
ung-abscess-versus-empyema.html 
Plain film 
• Can resemble a pleural effusion and can mimic a peripheral 
pulmonary abscess, although a number of features usually 
enable distinction between the two  empyema vs lung 
abscess.  
• Pleural fluid is typically unilateral or markedly asymmetric.   
• Empyemas usually: 
• form an obtuse angle with the chest wall 
• unilateral or markedly asymmetric whereas pleural 
effusions are (if of any significant size) usually bilateral and 
similar in size .   
• lenticular in shape (bi-convex), whereas pleural effusions 
are crescentic in shape (i.e concave towards the lung) 
http://radiopaedia.org/articles/empyema-vs-
pleural-effusion 
Meniscus sign indicative of a pleural 
effusion 
http://quizlet.com/15693486/radiology-exam-
i-review-images-flash-cards/ 
Chest X-Ray Empyema-pus in left side 
of Chest 
http://www.drgokhale.com/img/gallery/Thora
cic%20Surgery/img46.jpg 
X-ray showing empyema on right side 
http://www.laparoscopyindia.com/chest-
diseases/empyema 
Loculated empyema 
(A) Chest radiograph showing pleural-based 
opacity (arrow) with tapering obtuse margins 
in left hemithorax; (B) axial contrast-enhanced 
CT scan showing loculated collection 
(arrowhead) with peripherally enhancing thick 
walls 
http://www.ijri.org/viewimage.asp?img=Indian
JRadiolImaging_2013_23_4_313_125577_f3.jp
g 
Calcified empyema 
(A) Chest radiograph showing volume loss right hemithorax 
with veil-like calcifi ed (arrow) pleural opacity; (B) axial 
contrast-enhanced CT scan showing evidence of calcifi ed 
chronic empyema (arrow) with proliferation of extrapleural 
fat and crowding of ribs suggestive of volume loss in right 
hemithorax 
http://www.ijri.org/viewimage.asp?img=Indian
JRadiolImaging_2013_23_4_313_125577_f4.jp
g 
Treatment of empyema 
Treatment, as a rule, is based on antibiotic 
therapy and complete drainage of the liquid 
to allow total lung re-expansion. 
Antibiotics 
• The mainstay of all therapies in parapneumonic 
effusions and empyemas is systemic antibiotic 
therapy. 
• Empirical antimicrobial therapy is initiated on the 
basis of its anticipated bactericidal activity against 
the suspected microbial pathogens and is 
changed when the susceptibilities of the infecting 
microorganism(s) are known. 
• Aminopenicillins, penicillins combined with β-
lactamase inhibitors (e.g. co-amoxiclav or 
piperacillin-tazobactam) and cephalosporins 
show good penetration of the pleural space. 
Antibiotics 
• Aminoglycosides should be avoided as they have poor 
penetration into the pleural space and may be inactive in the 
presence of pleural fluid acidosis. 
• Macrolide antibiotics are not indicated unless there is 
objective evidence or high clinical index of atypical pathogens. 
• Clindamycin achieves a good penetration of the infected 
pleural space and can be used either alone or in combination 
with a cephalosporin. 
• Intravenous administration of antibiotics is often appropriate 
initially but can be changed to oral when objective clinical and 
biochemical improvement  has been observed.  
• The duration of treatment is often continued for at least 3 
weeks. 
http://www.researchgate.net/profile/Valentina_Pinelli/publication/49736268_Practi
cal_management_of_pleural_empyema/file/504635166b0a21eb33.pdf 
Chest tube drainage 
• Lack of response to antibiotics, demonstrated by lack of 
clinical and radiological improvement, is a strong indication 
for chest tube drainage.  
• The optimum size of chest tube and duration of drainage is 
still under discussion. 
• Removal of the chest drain is appropriate depending on two 
factors: first, after radiological confirmation of successful 
pleural drainage, i.e. reduction in the size of pleural collection 
on the chest x-ray or thoracic ultrasound; and second, 
objective evidence of sepsis resolution, i.e. improvement in 
temperature and clinical condition and decreasing 
inflammatory markers. 
http://www.researchgate.net/profile/Valentina_Pinelli/publication/49736268_Practi
cal_management_of_pleural_empyema/file/504635166b0a21eb33.pdf 
Chest tube 
http://lungcancer.ucla.edu/adm_proc_chest.ht
ml 
Chest drain 
http://www.surgical-tutor.org.uk/default-
home.htm?specialities/cardiothoracic/chest_d
rains.htm~right 
Fibrinolytic agents 
• Fibrinolytics  induce enzymatic lysis of adhesions and 
debridement. 
• Today, fibrinolytic agents are recommended  when chest 
tube drainage and a course of adequate antibiotics have 
failed to improve the situation, and when the effusion is 
loculated. 
• Optimal dosage and timing of  therapy are unknown.  
• Most studies have used single doses of 250,000 IU 
streptokinase or 100,000 IU urokinase.  
• Usually, the procedure is carried out as follows: the 
fibrinolytic substance is diluted in 100 mL saline and 
instilled via the chest tube.  The tube is then clamped for 1–
4 h. The instillation is usually repeated once daily, and is 
continued for several days, sometimes for periods of up to 
2 weeks. 
http://www.ersj.org.uk/content/10/5/1150.full
.pdf 
Thoracoscopy 
• Thoracoscopy has been used as an alternative to 
thoracotomy in pleural effusion due to lung infection, 
because it allows the mechanical removal of infected 
material and permits lung re-expansion. 
• It is possible to open multiple loculations and aspirate 
the purulent liquid, removing the fibrinous adhesions, 
including the layer on visceral pleura. 
• Most thoracoscopic empyema treatments are 
performed and described by surgeons using classical 
three-entry port intervention under general 
anaesthesia and double-lumen intubation (VATS). 
• VATS can disrupt intrapleural adhesions and achieve 
complete drainage of loculated effusions refractory to 
intracavitary thrombolytic therapy 
http://www.researchgate.net/profile/Valentina_Pinelli/publication/49736268_Practi
cal_management_of_pleural_empyema/file/504635166b0a21eb33.pdf 
Surgical decortication 
• Decortication is a surgical procedure that removes a 
restrictive layer of fibrous tissue overlying the lung, 
chest wall, and diaphragm. The aim of decortication is 
to remove this layer and allow the lung to reexpand. 
When the peel is removed, compliance in the chest 
wall returns, the lung is able to expand and deflate, 
and patient symptoms improve rapidly 
http://emedicine.medscape.com/article/1970123-overview 
•  It is still indicated in cases when, 6 months after the 
acute stage, the pleura is still thickened and the 
patient’s pulmonary function is sufficiently reduced to 
limit normal activities. 
http://www.researchgate.net/profile/Valentina_Pinelli/publication/49736268_Practi
cal_management_of_pleural_empyema/file/504635166b0a21eb33.pdf 
Complications of empyema 
• Bronchopleural fistula 
• Empyema necessitatis  
• Empyema necessitatis occurs when an empyema 
extends through the parietal pleura into the 
surrounding tissues. EN has become less common 
with the routine drainage of empyema and 
antibiotic use. Most cases reported in the 
modern literature have been in 
immunocompromised patients. 
http://journal.publications.chestnet.org/article.aspx?articleID=1086918 
• Inability to re-expand the trapped lung and 
difficulty in achieving therapeutic drug levels in 
pleural fluid  
